Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

BillionerOfKing Apr. 29 at 9:28 PM

$PRAX Current Stock Price: $322.20 Contracts to trade: $320.0 PRAX May 15 2026 Call Entry: $22.00 Exit: $32.60 ROI: 48% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

3_19 Apr. 28 at 2:25 PM

$PRAX this is all over the place today day. Big boys playing with their toys.

0 · Reply

3_19 Apr. 24 at 8:03 PM

$PRAX solid close.

0 · Reply

Trainguy1 Apr. 23 at 12:08 PM

$PRAX @S_Franconi These are Praxis’s lead drug candidates: - Ulixacaltamide - treats essential tremor - Relutrigine - treats Developmental and Epileptic Encephalopathies [DEEs] Both of these drug candidates have been granted breakthrough therapy designation (BTD) by the FDA. BTD provides the following benefits for drug candidates intended to treat serious diseases, and which offer substantial treatment advantages over existing options: - intensive FDA guidance - rolling review - priority review - more frequent meetings and correspondence - enhanced manufacturing support Ulixacaltamide PDUFA date: Jan. 29, 2027 Relutrigine PDUFA date: Sept. 27, 2026

1 · Reply

Trainguy1 Apr. 18 at 1:57 PM

$PRAX @S_Franconi More info on Praxis at AAN: https://praxismedicines.com/2026-aan-annual-meeting/

2 · Reply

Trainguy1 Apr. 18 at 1:18 PM

$PRAX @S_Franconi The 2026 American Academy of Neurology (AAN) Annual Meeting starts today, April 18, 2026, and runs through April 22, 2026, in Chicago, Illinois, and online. https://www.linkedin.com/company/praxis-precision-medicines-inc/

0 · Reply

AngusMacbeth Apr. 17 at 2:29 PM

$PRAX I’m amazed how little interest this company gets from retail given the science/drugs they are developing.

3 · Reply

KY3000 Apr. 17 at 2:25 PM

$PRAX 👍

0 · Reply

KY3000 Apr. 16 at 11:08 PM

$PRAX stop loses will be wrecked

0 · Reply

KY3000 Apr. 16 at 11:06 PM

$PRAX 111+ % tute owned. Date set with FDA, 7 months. Max pain coming

1 · Reply

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Apr 6, 2026, 9:08 AM EDT - 23 days ago

Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

Apr 6, 2026, 8:00 AM EDT - 23 days ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Apr 2, 2026, 4:01 PM EDT - 27 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 30, 2026, 4:01 PM EDT - 4 weeks ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 2, 2026, 11:50 AM EST - 2 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 20, 2026, 12:10 PM EST - 2 months ago

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Feb 19, 2026, 8:00 AM EST - 2 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 7:30 AM EST - 2 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 1:00 PM EST - 2 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 4:01 PM EST - 2 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 2, 2026, 9:57 AM EST - 3 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 8, 2026, 4:45 PM EST - 3 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 6, 2026, 11:15 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 4:03 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Dec 29, 2025, 9:48 AM EST - 4 months ago

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Dec 29, 2025, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 11, 2025, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 9, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 5, 2025, 1:10 PM EST - 5 months ago

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Dec 4, 2025, 4:10 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Nov 24, 2025, 1:00 PM EST - 5 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 20, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 20, 2025, 1:55 PM EST - 5 months ago

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Nov 18, 2025, 8:30 AM EST - 5 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 6 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 7, 2025, 12:30 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 16, 2025, 11:45 PM EDT - 6 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 2:14 PM EDT - 6 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 6 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 8:00 AM EDT - 6 months ago

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 7:09 AM EDT - 6 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Sep 29, 2025, 7:00 AM EDT - 7 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 10, 2025, 8:30 AM EDT - 8 months ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:01 PM EDT - 8 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 2, 2025, 10:00 AM EDT - 8 months ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Aug 25, 2025, 4:01 PM EDT - 8 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 14, 2025, 9:28 AM EDT - 9 months ago

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

Aug 7, 2025, 11:00 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 5:50 PM EDT - 9 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 10:00 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 4, 2025, 8:30 AM EDT - 9 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 8:30 AM EDT - 9 months ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2025

Jul 17, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jun 4, 2025, 8:10 AM EDT - 11 months ago

Praxis Precision Medicines Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 7, 2025, 3:26 PM EDT - 1 year ago

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Status Update

May 2, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: UBS Virtual CNS Day 2025

Mar 12, 2025, 2:30 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 9:10 AM EST - 1 year ago

Praxis Precision Medicines Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 11, 2025, 11:20 AM EST - 1 year ago

Praxis Precision Medicines Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:30 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Jan 15, 2025, 5:15 PM EST - 1 year ago

Praxis Precision Medicines Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 12, 2025, 9:00 PM EST - 1 year ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dec 18, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 1 year ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Dec 4, 2024, 2:00 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Nov 20, 2024, 5:00 AM EST - 1 year ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2024

Nov 11, 2024, 1:00 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Nov 6, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Earnings Call Transcript: Q3 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Study Result

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2024

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Praxis Precision Medicines Transcript: Jefferies Global Healthcare Conference

May 20, 2024, 10:00 AM EDT - 2 years ago

Praxis Precision Medicines Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Praxis Precision Medicines Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Praxis Precision Medicines Transcript: Study Update

Mar 6, 2024, 10:30 AM EST - 2 years ago

Praxis Precision Medicines Transcript: TD Cowen 44th Annual Health Care Conference 2024

Nov 28, 2023, 10:00 AM EST - 2 years ago

Praxis Precision Medicines Transcript: Piper Sandler 35th Annual Healthcare Conference

Oct 2, 2023, 9:00 AM EDT - 2 years ago

Praxis Precision Medicines Transcript: R&D Day 2023

Mar 3, 2023, 8:00 AM EST - 3 years ago

Praxis Precision Medicines Transcript: Study Result

May 9, 2022, 8:45 AM EDT - 4 years ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2022

Apr 27, 2022, 8:30 AM EDT - 4 years ago

Praxis Precision Medicines Transcript: Epilepsy Day 2022

BillionerOfKing Apr. 29 at 9:28 PM

0 · Reply

3_19 Apr. 28 at 2:25 PM

$PRAX this is all over the place today day. Big boys playing with their toys.

0 · Reply

3_19 Apr. 24 at 8:03 PM

$PRAX solid close.

0 · Reply

Trainguy1 Apr. 23 at 12:08 PM

1 · Reply

Trainguy1 Apr. 18 at 1:57 PM

$PRAX @S_Franconi More info on Praxis at AAN: https://praxismedicines.com/2026-aan-annual-meeting/

2 · Reply

Trainguy1 Apr. 18 at 1:18 PM

0 · Reply

AngusMacbeth Apr. 17 at 2:29 PM

$PRAX I’m amazed how little interest this company gets from retail given the science/drugs they are developing.

3 · Reply

KY3000 Apr. 17 at 2:25 PM

$PRAX 👍

0 · Reply

KY3000 Apr. 16 at 11:08 PM

$PRAX stop loses will be wrecked

0 · Reply

KY3000 Apr. 16 at 11:06 PM

$PRAX 111+ % tute owned. Date set with FDA, 7 months. Max pain coming

1 · Reply

Okadarlan Apr. 16 at 7:36 PM

$PRAX yeah crumble pos, short avarage after accumulation to the top for weeks is 310, we nearly in profit.

2 · Reply

Trainguy1 Apr. 16 at 6:40 PM

$PRAX The average Wall Street analyst’s 1-year price target is $623.94. Our most optimistic analyst from H.C. Wainwright is forecasting a price target of $1245. It could hit that high price after the Jan 29, 2027 PDUFA date for Ulixacaltamide.

1 · Reply

Trainguy1 Apr. 16 at 6:14 PM

$PRAX Praxis Precision Medicines is highlighting its essential tremor program, Ulixacaltamide, with 15 scientific presentations next week at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago (April 18–22, 2026) With all of those scientific presentations, I can’t see the share price ever dropping below $325 again. The price could go much higher.

0 · Reply

3_19 Apr. 16 at 4:34 PM

$PRAX How low will they bring it today?

0 · Reply

3_19 Apr. 16 at 2:11 PM

$PRAX On sale today

0 · Reply

3_19 Apr. 16 at 1:50 PM

$PRAX on sa today

0 · Reply

StockConsultant Apr. 16 at 1:27 PM

$PRAX Praxis Precision Medicines stock, watch for a to pof range breakout at https://stockconsultant.com/?PRAX

0 · Reply

AngusMacbeth Apr. 15 at 10:25 PM

$PRAX Decent volume today. nice to see.

0 · Reply

AngusMacbeth Apr. 15 at 4:56 PM

$PRAX Added a little at $336. Will add more if it drops to $330 today.

1 · Reply

KY3000 Apr. 15 at 2:16 PM

$PRAX I hope they dump this into 200s$

2 · Reply

R84877P Apr. 14 at 8:21 PM

$PRAX jumped to $370 after hours for a minute.. then back down. I'm keeping an eye on it

1 · Reply

Quantumup Apr. 14 at 6:36 PM

Raymond James (a/o 4/9)🏁 $RAPP and said: Initiate at Strong Buy, $66 PT; Building Rapport with RAP-219 in Bipolar Mania $XENE $PRAX BHVN MPLT VNDA JAZZ ALKS UCBJY Here's what else Raymond James had to say in its initiation report: https://x.com/Quantumup1/status/2044121544658694182?s=20

0 · Reply

Market Cap	8.97B
Revenue (ttm)	0.00
Net Income (ttm)	-303.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	363,500
Avg Vol	410,408
Day's Range	N/A - N/A
Shares Out	27.85M
Stochastic %K	23%
Beta	2.94
Analysts	Strong Sell
Price Target	$632.65